EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

[Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses

D Martín-Torregrosa, M Mansilla-Polo, D Morgado-Carrasco

Actas Dermo-Sifiliográficas · 2025-01 · 116 (1) · T55-T67

DOI: 10.1016/j.ad.2024.10.008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Actas Dermo-Sifiliográficas, 2025-01. Verfasst von D Martín-Torregrosa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Dermatología, Hospital Universitario y Politécnico La Fe, IIS La Fe, Valencia, Spain. Hauptthemen laut MEDLINE: Lupus Erythematosus, Cutaneous, Antibodies, Monoclonal, Humanized, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently approved for the management of moderate-to-severe systemic lupus erythematosus (SLE). In 2 clinical trials, it has proven effective to treat cutaneous signs. Although anifrolumab has not been indicated for cutaneous lupus erythematosus (CLE), multiple cases and case series (20 publications with a total of 78 patients) have shown good and rapid responses with this drug, both in subacute CLE and discoid lupus erythematosus, as well as in lupus panniculitis and perniosis. Two case reports of dermatomyositis have also experienced clinical improvement with anifrolumab. Clinical trials of this drug are ongoing for subacute CLE and discoid lupus erythematosus, systemic sclerosis, and progressive vitiligo. Its most common adverse effects are respiratory infections and herpes zoster. Anifrolumab may be a well-tolerated alternative in the management of CLE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, CutaneousAntibodies, Monoclonal, HumanizedLupus Erythematosus, SystemicHumansAutoimmune DiseasesAntibodies, MonoclonalSkin DiseasesClinical Trials as Topic

Stichwörter der Autor:innen

AnifrolumabDermatomiositisDermatomyositisEsclerodermiaLupusScleroderma

Substanzen

Antibodies, Monoclonal, HumanizedanifrolumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Servicio de Dermatología, Hospital Universitario y Politécnico La Fe, IIS La Fe, Valencia, Spain.
  • Servicio de Dermatología, Hospital de Figueres, Fundació Salut Empordà, Girona, Spain; Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain. Electronic address: morgadodanie…

Zitieren

APA

Martín-Torregrosa, D., Mansilla-Polo, M., & Morgado-Carrasco, D. (2025). [Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses. Actas Dermo-Sifiliográficas, 116(1), T55-T67. https://doi.org/10.1016/j.ad.2024.10.008

Vancouver

Martín-Torregrosa D, Mansilla-Polo M, Morgado-Carrasco D. [Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses. Actas Dermo-Sifiliográficas. 2025;116(1):T55-T67. doi:10.1016/j.ad.2024.10.008

BibTeX
@article{MartnTorregrosa2025,
  author = {Martín-Torregrosa, D and Mansilla-Polo, M and Morgado-Carrasco, D},
  title = {[Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2025},
  volume = {116},
  number = {1},
  pages = {T55--T67},
  doi = {10.1016/j.ad.2024.10.008}
}
Kostenlos starten →